Products
Pre-made Diridavumab benchmark antibody ( Whole mAb, anti-Influenza A HA2 therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-147
Pre-Made Diridavumab biosimilar, Whole Mab: Anti-Influenza A HA2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Diridavumab (CR6261) (INN) is a monoclonal antibody designed for the treatment of influenza A.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-147-1mg | 1mg | 3090 | Inquiry | Inquiry |
Size： 1mg | 10mg | 100mg
Description
| Products Name (INN Index) | Pre-Made Diridavumab biosimilar, Whole Mab: Anti-Influenza A HA2 therapeutic antibody |
| INN Name | Diridavumab |
| Target | Influenza A HA2 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | 3gbn:HL/3gbm:HL:IM/5c0s:HL |
| 99% SI Structure | None |
| 95-98% SI Structure | 4evn:AB:CD:IJ:OP:KL:EF:GH:MN |
| Year Proposed | 2014 |
| Year Recommended | 2015 |
| Companies | National Institute of Allergy and Infectious Diseases;Crucell |
| Conditions Approved | na |
| Conditions Active | Influenza A virus (H1N1) infections |
| Conditions Discontinued | na |
| Development Tech | na |
<